Q-omics provides the consensus-scored NIPA1 profile across patient tissues and cancer cell-line models. NIPA1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, NIPA1 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, NIPA1 RNA expression shows 19,577 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight MESO, HNSC, and UVM as cancer lineages where NIPA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NIPA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NIPA1 survival associations across molecular data types. NIPA1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NIPA1 RNA expression–survival associations across cancer types. High NIPA1 expression shows unfavorable associations in MESO, LIHC, UVM, BLCA and CESC, but favorable associations in KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify MESO as the clearest survival context for NIPA1 RNA expression.
This table summarizes NIPA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for NIPA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NIPA1 shows higher tumor expression in HNSC, COAD, LIHC, STAD, BLCA and KIRP. The HNSC box plot shows higher NIPA1 RNA expression in tumor versus normal tissue (log2 FC = +1.432, t-test p < 0.001).
This table shows molecular features associated with NIPA1 in patient tissues and cancer cell lines. In patient samples, NIPA1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NIPA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.
